Potential metabolomic biomarkers for evaluation of adriamycin efficacy using a urinary 1H-NMR spectroscopy

Journal of Applied Toxicology

Volumn 33, Issue 11, 2013, Pages 1251-1259

  Kim, Kyu Bong ^a   Yang, Ji Young ^b   Kwack, Seung Jun ^c   Kim, Hyung Sik ^d   Ryu, Do Hyun ^e   Kim, Yeon Joo ^e   Bae, Jung Yun ^e   Lim, Duck Soo ^e   Choi, Seul Min ^e   Kwon, Mi Jung ^e   Bang, Du Yeon ^e   Lim, Seong Kwang ^e   Kim, Young Woo ^e   Hwang, Geum Sook ^b   Lee, Byung Mu ^e  

^a Dankook University   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

^c Changwon National University   (South Korea)

^d Pusan National University   (South Korea)

^e Sungkyunkwan University   (South Korea)

Author keywords

1H NMR; Adriamycin; Biomarker; Gastric cancer; Metabolomics

Indexed keywords

2 OXOGLUTARIC ACID; DOXORUBICIN; HIPPURIC ACID; TAURINE; TRIMETHYLAMINE OXIDE; ANTINEOPLASTIC ANTIBIOTIC; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; MALE; METABOLOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STOMACH ADENOCARCINOMA; URINALYSIS; URINE LEVEL; ANIMAL; BAGG ALBINO MOUSE; DRUG SCREENING; HUMAN; METABOLOME; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUDE MOUSE; PROCEDURES; STOMACH NEOPLASMS; TUMOR CELL LINE; URINE;

MUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; METABOLOMICS; MICE, INBRED BALB C; MICE, NUDE; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884704635     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2778     Document Type: Article

References (50)

1. Albert DM, Plum LA, Yang W, Marcet M, Lindstrom MJ, Clagett-Dame M, DeLuca HF. 2005. Responsiveness of human retinoblastoma and neuroblastoma models to a noncalcemic 19-nor Vitamin D analog. J. Steroid Biochem. Mol. Biol. 97: 165-172.
2. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C. 1969. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol. Bioeng. 11: 1101-1110.
3. Azab SS, Salama SA, Hassan MH, Khalifa AE, El-Demerdash E, Fouad H, Al-Hendy A, Abdel-Naim AB. 2008. 2-Methoxyestradiol reverses doxorubicin resistance in human breast tumor xenograft. Cancer Chemother. Pharmacol. 62: 893-902.
4. Bernuzzi F, Recalcati S, Alberghini A, Cairo G. 2009. Reactive oxygen species-independentapoptosis in doxorubicin-treated H9c2 cardiomyocytes: role for heme oxygenase-1 down-modulation. Chem. Biol. Interact. 177: 12-20.
5. Blum RH, Carter SK. 1974. Adriamycin: a new anticancer drug with significant clinical activity. Ann. Intern. Med. 80: 249-259.
6. Cai Z, Zhao JS, Li JJ, Peng DN, Wang XY, Chen TL, Qiu YP, Chen PP, Li WJ, Xu LY, Li EM, Tam JP, Qi RZ, Jia W, Xie D. 2010. A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Mol. Cell. Proteomics 9: 2617-2628.
7. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nature Rev. Cancer 11: 85-95.
8. Cao Q, Wang Y, Zheng D, Sun Y, Wang Y, Lee VW, Zheng G, Tan TK, Ince J, Alexander SI, Harris DC. 2010I. L-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J. Am. Soc. Nephrol. 21: 933-942.
9. Carter SK. 1975. Adriamycin-a review. J. Natl. Cancer Inst. 55: 1265-1274.
10. Cascante M, Benito A, Zanuy M, Vizan P, Marin S, de Atauri P. 2010. Metabolic network adaptations in cancer as targets for novel therapies. Biochem. Soc. Trans. 38: 1302-1306.
11. Chan EC, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, Cavill R, Nicholson JK, Keun HC. 2009. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 8: 352-361.
12. De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, Thomas CJ, Deng CX. 2006. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int. J. Biol. Sci. 2: 179-185.
13. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. 2008. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18: 54-61.
14. Furukawa T, Fu X, Kubota T, Watanabe M, Kitajima M, Hoffman RM. 1993. Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue. Cancer Res. 53: 1204-1208.
15. Gamcsik MP, Constantinidis I, Glickson JD. 1991. In vivo 14N nuclear magnetic resonance spectroscopy of tumors: detection of ammonium and trimethylamine metabolites in the murine radiation induced fibrosarcoma 1. Cancer Res. 51: 3378-3383.
16. Gao H, Dong B, Liu X, Xuan H, Huang Y, Lin D. 2008. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal. Chim. Acta 624: 269-277.
17. Gewirtz DA. 1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57: 727-741.
18. Glunde K, Serkova NJ. 2006. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 7: 1109-1123.
19. Glunde K, Jacobs MA, Bhujwalla ZM. 2006. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev. Mol. Diagn. 6: 821-829.
20. Griffin JL, Shockcor JP. 2004. Metabolic profiles of cancer cells. Nat. Rev. Cancer 4: 551-561.
21. Hattingen E, Raab P, Franz K, Zanella FE, Lanfermann H, Pilatus U. 2008. Myo-inositol: a marker of reactive astrogliosis in glial tumors? NMR Biomed. 21: 233-241.
22. Hemming AW, Gallinger S, Greig PD, Cattral MS, Langer B, Taylor BR, Verjee Z, Giesbrecht E, Nakamachi Y, Furuya KN. 2001. The hippurate ratio as an indicator of functional hepatic reserve for resection of hepatocellular carcinoma in cirrhotic patients. J. Gastrointest. Surg. 5: 316-321.
23. Holmes E, Antti H. 2002. Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. Analyst 127: 1549-1557.
24. Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. 1998. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother. Pharmacol. 41: 147-154.
25. Kim HK, Park WS, Kang SH, Warda M, Kim N, Ko JH, Prince A, Han J. 2007. Mitochondrial alterations in human gastric carcinoma cell line. Am. J. Physiol. Cell Physiol. 293: C761-771.
26. Kim KB, Chung MW, Um SY, Oh JS, Kim SH, Na MA, Oh HY, Cho WS, Choi KH. 2008. Metabolomics and biomarker discovery: NMR spectral data of urine and hepatotoxicity by carbon tetrachloride, acetaminophen, and d-galactosamine in rats. Metabolomics 4: 377-392.
27. Kim KB, Lee BM. 2009. Metabolomics, a new promising technology for toxicological research. Toxicol. Res. 25: 59-69.
28. Kim KB, Um SY, Chung MW, Jung SC, Oh JS, Kim SH, Na HS, Lee BM, Choi KH. 2010a. Toxicometabolomics approach to urinary biomarkers for mercuric chloride (HgCl)- induced nephrotoxicity using proton nuclear magnetic resonance ((1)H NMR) in rats. Toxicol. Appl. Pharmacol. 249: 114-126.
29. Kim KB, Yang JY, Kwack SJ, Park KL, Kim HS, Ryu do H, Kim YJ, Hwang GS, Lee BM. 2010b. Toxicometabolomics of urinary biomarkers for human gastric cancer in a mouse model. J. Toxicol. Environ. Health A 73: 1420-1430.
30. Lee VWS, Wang Y, Qin X, Wang Y, Zheng G, Mahajan D, Coombes J, Rangan G, Alexander SI, Harris DCH. 2006. Adriamycin nephropathy in severe combined immunodeficient (SCID) mice. Nephrol. Dial. Transplan. 21: 3293-3298.
31. Manton DJ, Lowry M, Blackband SJ, Horsman A. 1995. Determination of proton metabolite concentrations and relaxation parameters in normal human brain and intracranial tumours. NMR Biomed. 8: 104-112.
32. Marshall CB, Krofft RD, Pippin JW, Shankland SJ. 2010. CDK inhibitor p21 is prosurvival in adriamycin-induced podocyte injury, in vitro and in vivo. Am. J. Physiol. Renal Physiol. 298: F1140-F1151.
33. Moreno A, Rey M, Montane JM, Alonso J, Arus C. 1993. 1H NMR spectroscopy of colon tumors and normal mucosal biopsies; elevated taurine levels and reduced polyethyleneglycol absorption in tumors may have diagnostic significance. NMR Biomed. 6: 111-118.
34. Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y. 2006. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother. Pharmacol. 57: 693-702.
35. Park JC, Hong YS, Kim YJ, Yang JY, Kim EY, Kwack SJ, Ryu do H, Hwang GS, Lee BM. 2009. A metabonomic study on the biochemical effects of doxorubicin in rats using (1)H-NMR spectroscopy. J. Toxicol. Environ. Health A 72: 374-384.
36. Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics. 2002. CA Cancer J. Clin. 55: 74-108.
37. Robertson DG, Watkins PB, Reily MD. 2011. Metabolomics in toxicology: preclinical and clinical applications. Toxicol. Sci. 120: S146-170.
38. Selivanov VA, Vizan P, Mollinedo F, Fan TW, Lee PW, Cascante M. 2010. Edelfosineinduced metabolic changes in cancer cells that precede the overproduction of reactive oxygen species and apoptosis. BMC Syst. Biol. 4: 135.
39. Serkova NJ, Niemann CU. 2006. Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics. Expert Rev. Mol. Diagn. 6: 717-731.
40. Serkova NJ, Spratlin JL, Eckhardt SG. 2007. NMR-based metabolomics: translational application and treatment of cancer. Curr. Opin. Mol. Ther. 9: 572-585.
41. Shaw RJ. 2006. Glucose metabolism and cancer. Curr. Opin. Cell Biol. 18: 598-608.
42. Shin VY, Wu WK, Ye YN, So WH, Koo MW, Liu ES, Luo JC, Cho CH. 2004. Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2. Carcinogenesis 25: 2487-2495.
43. Slupsky CM, Rankin KN, Wagner J, Fu H, Chang D, Weljie AM, Saude EJ, Lix B, Adamko DJ, Shah S, Greiner R, Sykes BD, Marrie TJ. 2007. Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. Anal. Chem. 79: 6995-7004.
44. Spratlin JL, Serkova NJ, Eckhardt SG. 2009. Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 15: 431-440.
45. Vangala S, Tonelli A. 2007. Biomarkers, metabonomics, and drug development: can inborn errors of metabolism help in understanding drug toxicity? AAPS J. 9: E284-297.
46. Vaughn AE, Deshmukh M. 2008. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome C. Nat. Cell Biol. 10: 1477-1483.
47. Wang Y, Wang Y, Feng X, Bao S, Yi S, Kairaitis L, Tay YC, Rangan GK, Harris DCH. 2001. Depletion of CD4+ T cells aggravates glomerular and interstitial injury in murine adriamycin nephropathy. Kidney Int. 59: 975-984.
48. Weljie AM, Newton J, Mercier P, Carlson E, Slupsky CM. 2006. Targeted profiling: quantitative analysis of 1H NMR metabolomics data. Anal. Chem. 78: 4430-4442.
49. Williams RE, Eyton-Jones HW, Farnworth MJ, Gallagher R, Provan WM. 2002. Effect of intestinal microflora on the urinary metabolic profile of rats: a (1)H-nuclear magnetic resonance spectroscopy study. Xenobiotica 32: 783-794.
50. Xu EY, Schaefer WH, Xu Q. 2009. Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways. Curr. Opin. Drug Discov. Devel. 12: 40-52.